Lineage Cell Therapeutics Inc (LCTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lineage Cell Therapeutics Inc (LCTX) has a cash flow conversion efficiency ratio of -0.174x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.62 Million) by net assets ($20.80 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of Lineage Cell Therapeutics Inc for the company's overall valuation and market capitalisation.
Lineage Cell Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1991–2024)
This chart illustrates how Lineage Cell Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lineage Cell Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lineage Cell Therapeutics Inc ranked by their cash flow conversion efficiency. Explore LCTX cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Agencia Comercial Spirits Ltd Class A Ordinary Shares
NASDAQ:AGCC
|
N/A |
|
Sarana Meditama Metropolitan
JK:SAME
|
0.011x |
|
Amplitude Surgical SAS
PA:AMPLI
|
0.029x |
|
Henan Provincial Communications Planning & Design Institute Co Ltd Class A
SHE:300732
|
0.025x |
|
Antibiotice Ia
RO:ATB
|
0.020x |
|
RiverNorth Flexible Municipal Income Fund II Inc
NYSE:RFMZ
|
N/A |
|
KGI Securities (Thailand) Public Company Limited
BK:KGI
|
0.180x |
|
Ernst Russ AG
XETRA:ERAG
|
0.067x |
Annual Cash Flow Conversion Efficiency for Lineage Cell Therapeutics Inc (1991–2024)
The table below shows the annual cash flow conversion efficiency of Lineage Cell Therapeutics Inc from 1991 to 2024. View Lineage Cell Therapeutics Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $77.01 Million | $-23.09 Million | -0.300x | +34.90% |
| 2023-12-31 | $62.02 Million | $-28.57 Million | -0.461x | -3228.58% |
| 2022-12-31 | $71.94 Million | $1.06 Million | 0.015x | +105.68% |
| 2021-12-31 | $90.90 Million | $-23.56 Million | -0.259x | -24.83% |
| 2020-12-31 | $95.13 Million | $-19.75 Million | -0.208x | +27.69% |
| 2019-12-31 | $111.25 Million | $-31.95 Million | -0.287x | +14.22% |
| 2018-12-31 | $92.25 Million | $-30.88 Million | -0.335x | -80.20% |
| 2017-12-31 | $164.26 Million | $-30.52 Million | -0.186x | +42.72% |
| 2016-12-31 | $130.51 Million | $-42.33 Million | -0.324x | +44.34% |
| 2015-12-31 | $76.45 Million | $-44.54 Million | -0.583x | +5.94% |
| 2014-12-31 | $62.72 Million | $-38.85 Million | -0.619x | +11.28% |
| 2013-12-31 | $42.26 Million | $-29.51 Million | -0.698x | +13.80% |
| 2012-12-31 | $24.29 Million | $-19.68 Million | -0.810x | -147.04% |
| 2011-12-31 | $41.46 Million | $-13.59 Million | -0.328x | -109.58% |
| 2010-12-31 | $49.43 Million | $-7.73 Million | -0.156x | +59.43% |
| 2009-12-31 | $11.05 Million | $-4.26 Million | -0.386x | -204.49% |
| 2008-12-31 | $-4.35 Million | $-1.60 Million | 0.369x | -9.33% |
| 2007-12-31 | $-3.05 Million | $-1.24 Million | 0.407x | -39.85% |
| 2006-12-31 | $-1.87 Million | $-1.26 Million | 0.677x | -90.59% |
| 2005-12-31 | $-196.58K | $-1.41 Million | 7.194x | +261.40% |
| 2004-12-31 | $344.77K | $-1.54 Million | -4.457x | -1756.11% |
| 2003-12-31 | $-2.43 Million | $-654.14K | 0.269x | -85.20% |
| 2002-12-31 | $-1.17 Million | $-2.13 Million | 1.818x | -94.39% |
| 2001-12-31 | $-99.09K | $-3.21 Million | 32.392x | +978.80% |
| 2000-12-31 | $1.32 Million | $-4.86 Million | -3.686x | -326.31% |
| 1999-12-31 | $5.08 Million | $-4.39 Million | -0.865x | +1.19% |
| 1998-12-31 | $2.40 Million | $-2.10 Million | -0.875x | -337.50% |
| 1997-12-31 | $6.50 Million | $-1.30 Million | -0.200x | +73.33% |
| 1996-12-31 | $2.80 Million | $-2.10 Million | -0.750x | 0.00% |
| 1995-12-31 | $2.80 Million | $-2.10 Million | -0.750x | -20.00% |
| 1994-12-31 | $3.20 Million | $-2.00 Million | -0.625x | -126.56% |
| 1993-12-31 | $5.80 Million | $-1.60 Million | -0.276x | +27.85% |
| 1992-12-31 | $3.40 Million | $-1.30 Million | -0.382x | -193.14% |
| 1991-12-31 | $4.60 Million | $-600.00K | -0.130x | -- |
About Lineage Cell Therapeutics Inc
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for neurological and ophthalmic conditions in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the age-related macular degeneration; OPC1, an allogeneic… Read more